PCSK9 Meets PRV: Regeneron’s $70 Mil. Bid To Catch Up To Amgen
This article was originally published in RPM Report
Regeneron and its partner Sanofi have become the first biopharma companies to buy a Priority Review Voucher. The $67 million price is a nice bonus for the seller, BioMarin, but probably not the start of a big new market for PRVs.